Fibrinolytic Activity in Multiple Myeloma

American Journal of Hematology

Volumn 74, Issue 4, 2003, Pages 231-237

  Yaǧci, Münci ^a,b   Sucak, Gülsan Türköz ^a   Haznedar, Rauf ^a  

^a Gazi Uniersity School of Medicine   (Turkey)

^b NONE   (Turkey)

Author keywords

Cytokine; Global fibrinolytic capacity; Multiple myeloma; Thromboembolism

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELPHALAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR; VINCRISTINE;

ADULT; ARTICLE; BLOOD VESSEL OCCLUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; FEMALE; FIBRINOLYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOEMBOLISM; VEIN THROMBOSIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-11; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0344443810     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10433     Document Type: Article

References (59)

1. Wiman B. The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis. Hematol Oncol Clin North Am 2000;14:325-338.
2. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. BMJ 1985;290:1453-1456.
3. Newland JR, Haire WD. Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991;96:602-604.
4. Zurborn KH, Duscha H, Gram J, Bruhn HD. Investigation of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin's lymphoma. Oncology 1990; 47:376-380.
5. Kyle RA, Lust JA. Monoclonal gammopathies of undertermined significance. Semin Hematol 1989;26:176-200.
6. Catovsky D, Ikoku NB, Pitney WR, Galton DAG. Thromboembolic complications in myelomatosis. BMJ 1970;3:438-439.
7. Talerman A. Clinico-pathological study of multiple myeloma in Jamaica. BMJ 1970;2:285-293.
8. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
9. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615.
10. Petaja J, Myllynen P, Rokkanen P, Nokelainen M. Fibrinolysis and spinal injury. Acta Chir Scand 1989;155:241-246.
11. Glaspy JA. Distubances in hemostasis in patients with B-cell malignancies. Semin Thromb Hemost 1992;18:440-448.
12. Sanchez-Avalos J, Soong BCF, Miller SP. Coagulation disorders in cancer. II. Multiple myeloma. Cancer 1969;23:1388-1398.
13. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinol 2002;13: 187-192.
14. Keren DF. Coagulation disorders in patients with monoclonal gammopathies. Hematol Oncol Clin North Am 1993;7(6):1153-1159.
15. Deitcher SR, Erban JK, Limentani SA. Acquired free Protein S deficiency associated with multiple myeloma: A case report. Am J Hematol 1996;51:319-323.
16. Gruber A, Blasko G, Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res 1986;42: 579-581.
17. Kyle R. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992;6:342.
18. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-854.
19. Amiral J, Malmejac A, Gin H, et al. Evaluation of the fibrinolytic potential on plasma. Physiological and pathological variations, and associations with cardiovascular disease risk factors. Fibrinol Proteol 1999;13(Suppl 1):1-10.
20. Nilehn JE, Nilsson IM. Coagulation studies in different types of myeloma. Acta Med Scand Suppl 1966;445:194-199.
21. Preston FE, Lee D. Fibrinolysis in myelomatosis. Acta Haematol 1972;47:65-70.
22. Perkins HA, Mackenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. Blood 1970;35:695-707.
23. Ogston D, Dawson AA, Adam HM. The fibrinolytic enzyme system in leukemia, myelomatosis and myeloproliferative diseases. Acta Haematol 1972;48:322-330.
24. Yildiz BO, Haznedaroǧlu IC, Kirazli Ş, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002; 87:3871-3875.
25. Atalar E, Özmen F, Haznedaroǧlu I, et al. Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation. Int J Hematol 2002; 76:192-195.
26. Carr ME, Zekert S. Abnormal clot retraction, altered fibrin structure, and abnormal platelet function in multiple myeloma. Am J Physiol 1994;266:H1195-H1201.
27. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991;5:197-206.
28. ten Cate JW, Van der Poll T, Levi M, ten Cate H, van Deventer SJH. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997;78:415-419.
29. Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol 1999;36(Suppl 3):14-20.
30. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999;10:65-70.
31. Bergonzelli GE, Kruithof EKO. Constitutive plasminogen activator inhibitor 1 (PAI-1) biosynthesis in human Hep G2 hepatoma cells is maintained by an autocrine factor. Thromb Haemost 1991; 66:222-225.
32. Healy AM, Gelehter TD. Induction of plasminogen activator inhibitor-1 in Hep G2 human hepatoma cells by mediators of the acute phase response. J Biol Chem 1994;269:19095-19100.
33. van Hirsbergh VWM, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988;72:1467-1473.
34. Bevilacqua MP, Schleef RR, Gimbrone MA Jr, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986;78:587-591.
35. van der Poll, Levi M, Buller HR, van Deventer SJ, de Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991;174:729-732.
36. Idel S, Kumar A, Zwieb C, Holiday D, Koenig KB, Johnson AR. Effects of TGF-β and TNF-α on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am J Physiol 1994; 267:L693-L703.
37. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxemia in chimpanzees: effect of interventions in the cytokine and coagulation cascade. Clin Sci 1995;88:587-594.
38. Mestries JC, Kruithof EK, Gascon MP, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosilated human interleukin 6 in baboons. Eur Cytokine Netw 1994;5:275-281.
39. 2 in sepsis. Studies in non-human primates following interleukin-1α administration and during lethal bacteremia. Blood 1995;86: 1027-1034.
40. Stouthard JML, Levi M, Hack E, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-742.
41. Paul SR, Barut BA, Bennett F, Cochran MA, Anderson KC. Lack of a role of interleukin 11 in the growth of multiple myeloma. Leukat Res 1992;16:247-252.
42. Spence MJ, Streiff R, Day D, Ma Y. Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in calu-1 lung carcinoma cells. Cytokine 2002;18:26-34.
43. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990;346:74-76.
44. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000;95:577-580.
45. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clottting factors, and long term incidence of ischaemic heart disease in the Norwick Park Heart Study. Lancet 1993;342:1076-1079.
46. Schulman S, Wiman B and the duration of anticoagulation (DURAC) trial study group. The significance of hypofibrinolysis for the risk of recurrence of venous thrombosis. Thromb Haemost 1996;75:607-611.
47. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thrombosis. Arch Intern Med 1991;151:1721-1731.
48. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001;85:390-394.
49. Canavese C, Stratta P, Pacitti A, et al. Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes. Clin Nephrol 1982;17:82-89.
50. Sartori MT, Patrassi GM, Rigotti P, et al. Improved fibrinolytic capacity after withdrawal of steroid immunosupression in renal transplant recipients. Transplantation 2000;69:2116-2121.
51. Bazzan M, Pannochia A, Tarella C, et al. Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration. Haematologica 1993; 78:105-110.
52. Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997;17:3399-3405.
53. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.
54. Cermak J, Nigel SK, Ronald RB, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-520.
55. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GD. Association of blood rheology and IL-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999;104: 246-257.
56. Koenig W, Sund M, Frohlich M, et al. C-reactive protein a sensitive marker of inflammation predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study, 1984-92. Circulation 1999;99:237-242.
57. Wakefield TW, Greenfield LJ, Rolfe MW, et al. Inflamatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis. Thromb Haemost 1993;69:164-172.
58. Kamphuisen PW, Eikenboom JCJ, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81:680-683.
59. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001;115:3-12.